SPAC: Translational Development Acquisition Corp. (TDAC)
Company
SPAC: Translational Development Acquisition Corp. (TDAC)
Dec 23, 2024
SPAC
Unit Split- SPAC/IPOIPODec 2024Unit Split · Feb 2025SPAC/IPOIPODec 2024Unit Split · Feb 2025
- LOILOILOILOI
- AgreementDealAgreementDeal
- Merger voteVoteMerger voteVote
- MergerMergerMergerMerger
SPAC/IPO · Dec 2024 · Unit Split · Feb 2025
The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business, industry, sector, or geographical location, and intends to focus on industries that complement its management team’s background, and intends to capitalize on the ability of its management team to identify and acquire a business.
The Company’s management team is led by Michael B. Hoffman, its Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and Avanindra C. Das, Chief Financial Officer. In addition, the Board includes E. Premkumar Reddy, Curtis T. Keith, Matthew A. Kestenbaum and Christopher Jarratt.
BTIG, LLC is acting as sole book-running manager for the offering.
Chart/Sentiment
Financials
Translational Development Acquisition Corp. (TDAC)
| Period end | Trust Assets |
|---|---|
| 2026-06-30 | 157.3 m USD |
| 2025-12-31 | 181.7 m USD |
| 2024-12-31 | 174.4 m USD |
| 2023-12-31 | 0 USD |
Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.










